Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pai Life Sciences Inc. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is assigned to 1 distinct examiner and is located within a single art unit. Such a focused portfolio suggests that the company's current interactions with the patent office are limited to a single specific technological inquiry or application.
GANGLE, BRIAN J serves as the busiest examiner for this entity, holding the active matter. Because there is only the reported action in total, this examiner manages the whole of the company's current pending workload. The concentration of the case in a single art unit means that the prosecution strategy does not need to account for multiple departmental standards. Instead, the applicant can focus on the specific examination criteria of the distinct examiner to advance the matter toward resolution. This singular focus allows for a highly tailored response strategy that addresses the specific technical hurdles identified by the examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275463 | VACCINE AND METHODS FOR PREVENTING FILARIASIS AND DIROFILARIASIS | GANGLE, BRIAN J | 48d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275463 | VACCINE AND METHODS FOR PREVENTING FILARIASIS AND DIROFILARIASIS | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | 48d | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial